Long-term Outcomes of Perioperative CapeOx for Advanced Gastric Cancer with Extensive Lymph Node Metastasis (OGSG1701)
2025
Efficacy and Safety of Irinotecan-based therapy in Elderly Patients with Advanced Gastric Cancer: Subgroup Analysis of the RINDBeRG Trial
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402)
Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701
大型3型/4型胃癌に対する術前S-1＋CDDP＋DTX併用療法による第II相試験（OGSG 1402）：5年長期成績
Tumor Response Predicts Survival Time of Ramucirumab Plus Irinotecan in Advanced Gastric Cancer: An Exploratory Analysis of the Phase III RINDBeRG Trial
高度リンパ節転移を伴う進行胃癌に対する周術期Capecitabine＋Oxaliplatin (CapeOx)療法の第II相試験(OGSG1701)の最終生存解析
A Multicenter Phase 2 Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for large type 3 or type 4 gastric cancer Final outcomes (OGSG1902)
胃癌へのICI導入後におけるConversion手術の実際 -高齢者に着目したリアルワールドデータ(OGSG2301)-